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Purpose: To determine the contribution of surveillance mammography to the early detec-
tion of metachronous contralateral breast cancer (MCBC) and to assess its impact on the
survival of breast cancer patients with relation to compliance.
Method: Breast cancer patients (5589) were identified using files from the regional cancer
registry of the Comprehensive Cancer Centre North Netherlands (CCCN Groningen, The
Netherlands). The programme sensitivity and the impact on prognosis of follow-up mam-
mography with relation to compliance were evaluated in 114 patients who developed MCBC
during hospital follow-up.
Results: The cumulative MCBC incidence rate at year 10 was 3.4% (95% CI: 2.8–4.0%). The
programme sensitivity of surveillance mammography was 59.6% (95% CI: 50.6–68.7). In
patients who complied with annual mammography, sensitivity was increased to 70.8%
(95% CI: 61.7–80.0). Patients with MCBCs detected by routine mammography have better
survival rates than patients with MCBCs detected by other means (HR: 3.18; 95% CI: 1.59–
6.34). Though there was a trend towards improved survival in patients being compliant
with regular clinical follow-up (HR: 1.69; 95% CI: 0.72–3.96), this was not the case for
patients being compliant with annual mammography (HR:1.02; 95% CI:0.50–2.09).
Conclusion: Mammography is a valuable tool for the early detection of MCBC during hospi-
tal follow-up of breast cancer patients and is probably beneficial to survival. The utilisation
of follow-up surveillance in breast cancer patients and its potential impact on survival
deserve further investigation.
 2009 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved.
fax: +31 50 3614493.
L (G.H. De Bock).
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Contralateral breast cancer (CBC) is the most common second
primary malignancy in patients with a history of breast can-
cer.1 For metachronous contralateral breast cancer (MCBC) a
constant annual incidence of 0.3–1.0% is observed.2–6
Contralateral surveillancemammography is recommended
in the follow-up of patients treated for breast cancer and aims
at early detection of MCBC to optimise the outcome.7–9 Obser-
vational studies suggest that a secondary primary tumour
detected before its symptomatic onset has a favourable impact
on the survival of patients with MCBC.10,11 However, the sur-
vival benefit of diagnosing MCBC by mammography has not
yet been studied thoroughly.12,13 Mammography surveillance
in breast cancer follow-uphas been shown to be underutilised,
with the proportion of patients receiving a contralateral mam-
mography varying from 80% in the first year to 60% in the fifth
year of follow-up.14–16 This study was designed to evaluate the
diagnostic value of annual surveillancemammography and its
impact on survival. In addition, the compliance with annual
mammography was evaluated in MCBC patients, as was its
potential impact on the diagnostic performance of mammog-
raphy and MCBC patient survival.
2. Patients and methods
2.1. Settings and subjects
All the consecutive breast cancer patients diagnosed in four
hospitals in the North Netherlands (an academic hospital, a
large teaching hospital and two non-teaching hospitals) from
January 1989 to January 2003 were selected from the files of
the regional cancer registry of the Comprehensive Cancer
Centre North Netherlands (CCCN Groningen, The Nether-
lands). This cancer registry contains data on diagnosis, stage
and treatment, actively abstracted from the patients’ medical
records in all hospitals within the CCCN catchment area using
the registration and coding manual of the Dutch Association
of Comprehensive Cancer Centres. Passive follow-up of the
vital status through municipal population registries was con-
ducted. The censoring date was 5th January 2007.
All women with newly diagnosed breast cancer were in-
cluded. A new primary tumour was defined as any new tu-
mour that is not a recurrence or a direct extension of a
known tumour. All women with evidence of distant metasta-
sis at the moment of primary diagnosis were excluded, as
were patients who had a prior cancer other than non-mela-
noma skin cancer. A total of 5589 women were selected.
The occurrence of any subsequent MCBC was ascertained
by means of computerised record linkage. MCBC was defined
as any contralateral breast cancer occurring at least 6 months
after the first breast cancer. All other contralateral cancers
were considered as synchronous bilateral breast cancers. Pa-
tients with synchronous bilateral breast cancer (N = 94) were
excluded from the cohort and thus the final cohort consisted
of 5495 patients with primary ipsilateral breast cancer.
Of these 5495 women diagnosed with ipsilateral breast
cancer, MCBC was reported in 139 patients during follow-up.
For each of these patients, four to five patients without
evidence of MCBC (n = 597) – matched for hospital of diagno-sis, age at first primary tumour and duration of follow-up –
were selected randomly from the cohort. Follow-up informa-
tion was retrieved actively from medical documents in hospi-
tals for all 736 patients in our study. Follow-up information
was not available for 67 patients (12 with MCBC and 55 with-
out MCBC). For 13 patients, the MCBC was diagnosed after the
hospital follow-up had ended, thus these MCBCs were not in-
cluded in the evaluation of the contribution of surveillance
mammography. Therefore, the study finally included 656
breast cancers with 114 occurrences of MCBC during hospital
follow-up and 542 non-MCBCs.
2.2. Definitions
Surveillance mammography was defined as mammography
undertaken with or without physical breast examination and
other tests, in patients without any symptoms of relapse.
The programme sensitivity of surveillance mammography
was evaluated by calculating the number ofMCBCs as detected
bymammography divided by the total number of MCBC. Spec-
ificity was defined as the proportion of normal mammograms
(BIRADS 1 and 2) out of the mammograms of the 542 patients
without evidence of MCBC. All mammograms with BIRADS 3,
4 and 5 were considered as suspect formalignancy. In the case
of BIRADS 3 the strategywas to perform additional diagnostics
or to repeat the mammogram after 6 months, depending on
the other patient characteristics. For mammograms without
BIRADS classification, there was a classification with four cat-
egories (negative/benign/doubtful/malignancy). Negative and
benign findings were categorised as BIRADS 1 and 2, doubtful
findings which needed further tests were considered as BIR-
ADS 3 or BIRADS 4, and those highly suggestive of malignancy
were considered as BIRADS 5. The follow-up was considered as
over when the patient was diagnosed with distant metastases,
when there was a note in the files that the patient was dis-
charged from further hospital follow-up, when the patient was
referred to the National Breast Cancer Screening Programme,
when the patient was transferred to a general practitioner for
further follow-up or when the patient died. Overall survival
and distant metastasis-free survival of MCBC patients were
measured from the date of diagnosis of the first breast cancer.
Compliance with routine clinical examination and routine
mammography was considered for patients with MCBC diag-
nosis. If the interval between the diagnosis of MCBC and the
last clinical examination was less than or equal to the sched-
uled interval of clinical examinations (2–6 months in the first
year; 4–8 months in the second year; 10–14 months in the fol-
lowing year), the patient was considered to be compliant with
routine follow-up. If the interval between MCBC diagnosis
and the previous mammography was less than or equal to
14 months, the patient was considered to be compliant with
annual mammography.
Patients with MCBCs were divided into three groups by
mode of detection. ‘Routine mammography’ consisted of pa-
tients with MCBC detected by mammography alone in routine
follow-up. ‘Routine others’ consisted of patients with MCBC
detected in other ways, usually physical examination, during
routine follow-ups with or without mammography. ‘Interval’
consisted of patients with MCBC presenting between two
scheduled follow-up appointments.
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The incidence of MCBC and the confidence intervals (95% CIs)
were calculated by the use of life tables. Both the sensitivity
and the specificity of the mammography and their 95% CIs
were calculated. Generalized estimating equations (GEEs)were
used to estimate the 95% CIs for specificity estimates, which
accounted for dependent outcomes among women who re-
ceivedmore than onemammography during the study period.
In addition, positive predictive values (PPVs) were calculated.
Themode of detection of MCBCwas comparedwith v2 tests
among groups with regard to the year of first tumour, patient
age at MCBC, time to MCBC occurrence from first tumour
and MCBC characteristics. Kaplan–Meier survival analysis
was used to compare the overall and distant metastasis-free
survival of the groups with regard to the mode of detection,
compliance with routine follow-up visit and compliance with
annual mammography. The association of mode of detection
with the survival of MCBC patients was examined by a multi-
variate Cox proportional hazard model, adjusted for tumour
characteristics at the first breast cancer and time from first tu-
mour to MCBC. The impact (hazard ratios) of compliance with
routine follow-up visits and annual mammography on sur-
vival was evaluated by univariate Cox proportional analysis.
3. Results
3.1. Incidence of MCBC
Of the 5495 women diagnosed with ipsilateral breast cancer,
MCBCs were reported in 139 patients. The cumulative MCBC
incidence rate at years 5 and 10 was 2.0% (95% CI: 1.6–2.4%)
and 3.4% (95% CI: 2.8–4.0%), respectively (see Fig. 1).
3.2. Compliance, programme sensitivity and specificity
of mammography
One hundred and fourteen MCBCs were included in the eval-
uation of the contribution of surveillance mammography of
patients followed up in hospital. Nine (7.9%) patients were
considered as not complying with routine clinical examina-Fig. 1 – MCBC after primary treatment in ipsilateral breast
cancer patients.tions because they missed at least the former scheduled clin-
ical examinations. Eighteen (15.8%) patients were considered
as not complying with annual mammography because they
missed at least the previous scheduled mammography.
The programme sensitivity of surveillance mammography
was 59.6% (68/114; 95% CI: 50.6–68.7%; see Table 1). In the 105
patients complying with routine clinical examination, the
sensitivity was 64.8% (68/105; 95% CI: 55.6–73.9%). In the 96
patients complying with annual mammography, the sensitiv-
ity was 70.8% (68/96; 95% CI: 61.7–80.0%). The specificity of
mammography was 98.3% (95% CI: 97.9–98.7%).
3.3. Positive predictive values related to BIRADS scores
(if available)
For 40% (n = 1392) of the mammograms the BIRADS score was
available. The PPVs for BIRADS 3, 4 and 5 were 0% (0/12), 25%
(10/40) and 91% (19/21), respectively. The overall PPV for the
mammograms with BIRADS classification regarding the pres-
ence of MCBCwas 40% (29/73) which is somewhat higher than
the PPV related to the mammograms without BIRADS classifi-
cation (31%; 39/125).
3.4. Mode of detection
Forty-two (36.8%) MCBCs were detected by mammography
alone. Thirty-three (29.0%) MCBCs were in the ‘routine others’
group, of which seven (6.2%) MCBCswere detected by physical
examination alone, 26 (22.8%) were identified by both physical
examination and mammography. Thirty-nine (34.2%) tu-
mours were diagnosed as interval cancers.
There were trends indicating that MCBC was more likely to
be detected by mammography in patients with the first tu-
mour diagnosed after 1994 (v2 = 15.075, P = 0.005) and in pa-
tients with MCBC at pathological T stage 1 or Tis (v2 = 5.925,
P = 0.052; see Table 2).
3.5. Comparison of MCBC patient survival by mode of
detection
The patients with MCBC detected by mammography alone
had better overall survival and distant metastasis-free sur-
vival rate than patients with MCBC detected by ‘routine oth-
ers’ and ‘interval’. (Log-rank = 11.598, P = 0.003 and Log-
rank = 10.401, P = 0.006, Figs. 2a and b).
Multivariate analysis indicates that the patients with
MCBC detected by mammography have better survival rates
than patients with MCBC detected by other means during rou-
tine follow-up (HR: 2.59; 95% CI: 1.17–5.75), and with MCBC
arising as interval cases (HR: 3.63; 95%CI: 1.74-7.54). When
we combined ‘routine others’ and ‘interval’, due to the over-
lap of the 95% CIs of the HRs, the HR of death was 3.18 (95%
CI: 1.59–6.34) in patients with MCBC detected by other means
compared to patients with MCBC detected by routine mam-
mography alone. Patients with a first tumour at the patholog-
ical T2/3/4 stages have worse survival rates (HR: 1.90; 95% CI:
1.09–3.30) than patients with a first tumour at the pathological
T1/Tis stage. Patients with involved lymph nodes at first tu-
mour diagnosis have worse distant metastasis-free survival
rates (HR: 1.91; 95% CI: 1.09–3.35) than those without involved
Table 1 – Sensitivity of mammography in follow-up of breast cancer patients.
Patients n/N Sensitivity
% 95% CI
All patients (programme sensitivity) 68/114 59.6 50.6–68.7
Compliant with routine clinical examination 68/105 64.8 55.6–73.9
Compliant with annual mammography 68/ 96 70.8 61.7–80.0
Table 2 – Comparison of mode of detection for 114 MCBCs.
Characteristics Routine mammography (n = 42) Routine others (n = 33) Interval (n = 39) v2 P value
Year of diagnosis of MCBC
1989–1993 1 (9) 2 (18) 8 (73) 15.075 0.005
1994–1998 19 (37) 21 (41) 11 (22)
1999–2004 22 (42) 10 (19) 20 (39)
Time from first tumour
6 months 10 (39) 9 (34) 7 (27) 1.007 0.907
2 years 20 (37) 15 (28) 19 (35)
5 years 12 (35) 9 (27) 13 (38)
Age group at MCBC
<50 5 (23) 6 (27) 11 (50) 4.359 0.628
50–59 11 (37) 9 (30) 10 (33)
60–74 16 (40) 11 (28) 13 (32)
75+ 10 (45) 7 (32) 5 (23)
Pathologic T stage
pT1/Tis 36 (47) 19 (25) 22 (28) 5.925 0.052
pT2/3/4 5 (21) 11 (46) 8 (33)
Missing 1 (8) 3 (23) 9 (69)
Pathologic N stage
N0 26 (36) 20 (27) 27 (37) 1.796 0.407
N+ 10 (36) 11 (39) 7 (25)
Missing 6 (46) 2 (15) 5 (39)
Histology 1.691 0.429
Invasive 36 (36) 31 (31) 33 (33)
Non-invasive 6 (43) 2 (14) 6 (43)
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first tumour have worse overall and distant metastasis-free
survival rates than patients with MCBC occurring later (HR:
0.86; 95% CI: 0.76–0.96 and HR: 0.86; 95% CI: 0.77–0.95, respec-
tively; Table 3).
3.6. Comparison of MCBC patient survival by compliance
In addition, we evaluated the potential impact of compliance
with routine clinical examinations and compliance with an-
nual mammography on MCBC patient survival. Nine patients
who missed at least the former scheduled clinical examina-
tions showed worse survival (HR: 1.69; 95% CI: 0.72–3.96)
and distant metastasis-free survival (HR: 1.91; 95% CI: 0.82–
4.45) but neither result was statistically significant due to
the small sample of non-compliant patients (see also Fig. 2c
and d). There is no significant association of survival (HR:
1.02; 95% CI: 0.50–2.09) or distant metastasis free-survival
(HR: 1.00; 95% CI: 0.19–2.04) with compliance with annual
mammography in patients with MCBC. The survival curve
of the compliant group was crossed with the one of non-com-
pliant group (see Fig. 2e and f).4. Discussion
This study is one of the largest studies to evaluate the impact
of surveillance mammography on the survival of MCBC pa-
tients. The cumulative MCBC incidence rate at years 5 and
10 was 2.0% and 3.4%, respectively. The programme sensitiv-
ity of follow-up mammography was 60%. The patients with
MCBC detected by mammography alone had better survival
rates than patients with MCBC detected by other means with
or without mammography (P = 0.004). For patients complying
with annual mammography, sensitivity was increased to 71%.
Though there was a trend towards improved survival in pa-
tients being compliant with regular follow-up (HR: 1.69; 95%
CI: 0.72–3.96), this was not the case for patients being compli-
ant with annual mammography (HR: 1.02; 95% CI: 0.50–2.09).
Women diagnosed with a primary breast cancer are at in-
creased risk of developing a second breast cancer. Markedly
increased risks of MCBC have also been observed among
breast cancer patients in many other studies.1,4,6,17 The an-
nual risk of developing MCBC remained constant at 0.3–0.4%
per year after treatment in this series, which indicates that
patients remain at risk of contralateral breast cancer for at
Fig. 2 – Survival (a, c, e) and distant metastasis-free survival (b, d, f) of patients with MCBC.
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studies.6 This emphasises on the importance of surveillance
and treatment of MCBC even at ten years after primary treat-
ment to prevent the increased morbidity and mortality
caused by MCBC.
We estimated the programme sensitivity of surveillance
mammography to be 60% and the specificity to be 98%. These
estimates are comparable with other studies, including stud-ies of the breast cancer screening programme (sensitivity: 58–
75%; specificity: 97–99%)18–20 and studies of the follow-up of
breast cancer survivors (sensitivity: 44%–70%).21–23 Reported
proportions of MCBC detected by mammography vary from
40% to 70% between studies because of dissimilarities in the
patient populations, the frequency of mammography and
MCBC case definition.2,21–23 Due to the biological behaviour
of tumours, some tumours will be missed by annual
Table 3 – Multivariate Cox regression analysis of prognosis in patients with MCBC
Factors Hazard ratio 95% CI P-value
Death
Method of detection
Routine mammography alone 1 0.003
Routine physical examination 2.59 1.17–5.75
Interval 3.63 1.74–7.54
Pathologic T stage of first tumour
pT1/Tis 1 0.023
pT2/3/4 1.90 1.09–3.30
Time between first tumour and MCBC (yrs) 0.86 0.76–0.96 0.008
Distant metastasis and Death
Method of detection
Routine mammography 1 0.011
Routine physical examination 2.09 1.00–4.37
Interval 2.90 1.45–5.78
Pathologic N stage of first tumour
N0 1 0.023
N+ 1.91 1.09–3.35
Time between first tumour and MCBC(yrs) 0.86 0.77–0.95 0.004
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mammograms to assess whether cancers had been missed
or should have been considered as real interval cancers,
which can be considered as a limitation of the study. The pro-
portion of MCBC detected by mammography alonewas 37% in
our study, which was less than the rate reported in the studies
mentioned above. There was a trend that occurred in younger
patients that MCBC is less likely to be detected by mammog-
raphy, and the efficacy of mammography was also questioned
in younger patients.23 The patients in our series are relatively
young than those in other studies, which could partly explain
the lower proportion of MCBC detected by mammography
alone.24 We found a statistically significant association be-
tween the method of MCBC detection and the year of diagno-
sis. The proportion of MCBC detected in this study by
mammography alone was higher when the patients devel-
oped MCBC after 1994. One review paper also implied that
the contribution of mammography appeared to be of increas-
ing importance over time.12 A possible explanation for this
could be technical improvements in mammography and the
more effective use of mammography, as a consequence of
the national guidelines on follow-up and the implementation
of a national breast cancer screening programme in this
country. Women with DCIS are at a 2–4-fold greater risk of
developing cancer in the contralateral breast than women
without prior DCIS.25 Due to the limited number of patients
with prior DCIS, we could not separately evaluate the value
of surveillance mammography in women with prior DCIS.
Since 2000, there is a guideline in the Netherlands to use
the BIRADS system. As a consequence, for about 60% of the
mammograms the BIRADS score was not available in this
study. The overall PPV for the mammograms with BIRADS
classification regarding the presence of MCBC was 40% which
is somewhat higher than the PPV related to the mammo-
grams without BIRADS classification (31%). The higher PPV
in mammograms with a BIRADS classification might be a
reflection of an improved classification. The higher the BIR-
ADS score, the higher the related PPV. It should be mentionedthat the follow-up information was collected only for a strat-
ified sample of this population (n = 656), including all patients
with a MCBC and a selection of patients without MCBC. As a
consequence, this sample does not give a reflection of the
true prevalence of MCBC, which was only 2.5% (139/5495) in
the original sample. It can be expected that the PPV will be
lower in clinical follow-up practice.
The tumour size of MCBC detected by mammography
alone was smaller than that found for ‘routine others’ and
‘interval’ cases, as expected, though the differences were
not statistically significant, probably due to the reduction of
sample size by missing values. The proportion of smaller tu-
mours (less than 2 cm) was much higher (86%) in MCBC de-
tected by mammography, which accords with the study by
Samant and colleagues.2 We did not find any significant dif-
ference in the histological characteristics of MCBC between
the patients with MCBC detected by mammography and other
methods.
The characteristics of the primary tumour were associated
with the overall survival rate and the distant metastasis-free
survival rate of MCBC patients. The mode of detection of
MCBC remained significantly associated with both the overall
survival rate and distant metastasis-free survival rate in
MCBC patients after adjustment for the first primary tumour
characteristics, which indicated that the impact of detection
mode on survival could not be explained by any difference
in the pathological stage of the first tumour.21,26 A popula-
tion-based study revealed that MCBC at stage II or higher
worsens the patient survival rate whereas the MCBC at stage
I does not.27 As with earlier diagnosis of first tumours, the
early detection of MCBC was associated with an 81% reduc-
tion in risk of breast cancer death in the SEER database.28
We presume the impact of the mode of detection of MCBC
on survival was mainly due to the early detection of MCBC
by mammography. Additionally, our results indicate that the
interval between MCBC occurrence and the first tumour was
associated with MCBC patient survival, which is in line with
another study.29 The goal of surveillance mammography not
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detection of ipsilateral tumour recurrences. One review found
that 30% of all ipsilateral tumour recurrences were detected
by mammography in patients after breast conserving surgery;
however, no significant reduction of mortality was found in
patients with ipsilateral tumour recurrences detected by
mammography.12 Further research is warranted to investigate
the impact of mammography on survival with regard to early
detection of ipsilateral tumour recurrence.
Although the benefit of mammography is unbiased by lead
time because survival was measured from the first primary
breast cancer, a length bias is unavoidable in studies compar-
ing mammography detected cancers with interval cancers.
The slow-growing MCBCs are more likely to be detected by
mammography. Nevertheless, although length bias was also
claimed to affect the evaluation of mammographic efficacy
in the breast cancer screening programme, periodic mam-
mography was well accepted as the most cost-effective meth-
od for screening for breast cancer in many countries,
supported by evidence from randomized controlled studies.30
Therefore, although the observed survival improvement asso-
ciated with the mode of detection of MCBC might be partially
explained by length bias, it appears that surveillance mam-
mography is effective for the early detection of MCBC and
for improving those patients’ survival.
Competing risk is always an issue when investigating the
prognostic factors of one disease with all-cause mortality.
The patients could die from diseases other than breast cancer.
It is reasonable to suppose that older patients are more likely
to die due to competing risks. However, patients with MCBC
detected by mammography alone were not younger than
those in the ‘routine others’ and ‘interval’ groups. The findings
were also not reversed when distant metastasis was taken
into account as a substitute for breast cancer specific mortal-
ity. Therefore, competing risk is unlikely to explain the better
survival in mammography detected MCBC patients.
Eighteen patients did not receive annual mammography in
the preceding 14 months. In other words, the interval be-
tween the tumour detection and the last mammography
was greater than 1 year for these patients. It is possible that
MCBCs were detected early by mammography where patients
complied with annual mammography. In this study, we found
a trend indicating that the sensitivity of mammography was
improved in patients being compliant with routine clinical
examinations and patients being compliant with mammogra-
phy. There was a trend of improvement of prognosis in pa-
tients who complied with routine follow-up, though the
differences were not statistically significant, probably due to
the small sample size of non-compliant patients. Regarding
compliance with mammography, we did not find a significant
association between the compliance with annual mammog-
raphy with the prognosis of patients with MCBC, despite the
11% (from 59.6% to 70.8%) improvement in the sensitivity of
annual mammography. Though annual mammography could
improve the early detection of MCBC and could improve the
chances of improving survival, it is not yet clear that the
detection of MCBC by mammography will result in better sur-
vival, due to the varying behaviour of tumours and the char-
acteristics of patients. The cohort in this study, though very
large in comparison to previous studies, is still too small toanswer these important questions. Our findings indicate that
the 11% improvement in sensitivity in compliant patients is
unlikely to be sufficient to reduce mortality among women
with MCBC, which is in line with another study.31 The same
analysis should be repeated with a much larger cohort of wo-
men. A generally considered disadvantage of routine follow-
up is that patients who had suspicious symptoms wait for
their clinic visit rather than going to hospital, which probably
worsens prognosis. Patients should be strongly advised to see
their doctors whenever suspicious symptoms are found.7,8
In summary, the risk of contralateral breast cancer re-
mains constant after primary breast cancer, even after 10
years at 0.3–0.4% per year. During routine follow-up, this
study convincingly shows that mammography can identify
MCBC at an early stage and thereby improve the survival of
these patients. Mammography is a valuable tool for the early
detection of MCBC during hospital follow-up of breast cancer
patients and is probably beneficial to survival. The utilisation
of follow-up surveillance in breast cancer patients and its po-
tential impact on survival deserve further investigation.Funding
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